Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data
The Transmitter – January 01, 2023
Source: OpenAlex
Summary
Debate surrounds the use of psilocybin, a potent hallucinogen, in a clinical trial for fragile X syndrome, highlighting the evolving field of psychedelics and drug studies. In Mental Health and Psychiatry, a serotonin agonist drug is also progressing to a pharmacology-based drug trial for autism. Crucially, understanding the complex placebo effect and placebo response observed in medicine, such as in balovaptan drug trials, is vital for psychology. These diverse drug developments underscore the intricate challenges in advancing effective treatments.
Abstract
Welcome to the April edition of Going on Trial, a monthly newsletter covering clinical trials and drug development for autism and related conditions.In this issue, we're talking about a serotonin agonist's path to trial for autism, debate around a trial of psilocybin for fragile X syndrome and an analysis of placebo responses in a clinical trial of the vasopressin blocker balovaptan.Feel free to email me at peter@spectrumnews.org with feedback on how this newsletter can better serve your needs as a researcher, and send me any tips you think readers should know about.In fact, this month's story on psilocybin